Company
Cerevel Therapeutics
Together we will deliver science that takes us closer to meaningful change for people with neurological and psychiatric disorders.
- Status
- Acquiredas of 2026-09-23Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Cambridge, MA, United States
Claim, correct or request removal
Record updated 28 September 2026
About
Cerevel Therapeutics (NASDAQ:CERE) is a public Biopharmaceutical company in Cambridge, MA. It is developing pre-commercial neuroscience compounds to treat a variety of Central Nervous System disorders including Parkinson’s, epilepsy and schizophrenia. Acquired by Abbvie August 2024.
About the company
- Status notes
- Acquired by Abbvie August 2024.
Exit
- Acquisition
- 2024-08
Loading relationship preview